Interim CEO Ann Gidner finishes her employment and leaves the position as CEO of AcuCort on August 9, 2020. Ann Gidner will be available to the company as a consultant to a limited extent during a transitional period after the termination of her employment. The work of recruiting a permanent CEO is ongoing as previously communicated.

"I want to thank Ann Gidner for her very strong contributions and commitment during this year, as well as for her continued support during the upcoming transitional period," says Ebba Fåhraeus, Chairman of the Board of AcuCort AB.

For further information, please contact

Ebba Fåhraeus, Chairman of the Board, AcuCort AB

Phone: +46 (0)73 400 04 33

Email: ebba@lysaeus.com (http://file:///C:/Users/kund/Desktop/ebba@lysaeus.com)

This information is information that AcuCort AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person above, on June 15, 2020.

About AcuCort AB (publ)

AcuCort develops and commercializes ISICORT®, a new fast-dissolving oral film to put on the tongue, based on a well-known cortisone substance - dexamethasone. ISICORT® is a smart product in a new, innovative, patented and user-friendly dosage form primarily for the treatment of severe and acute allergic reactions, croup in children and chemotherapy-induced nausea and vomiting (CINV). The bioequivalence study that forms the basis of the application for marketing approval in Europe was carried out with positive results and a national hybrid application has been submitted to the Swedish Medical Products Agency. Taken together, this strengthens the company's assessment that the time until commercialization of ISICORT® may be relatively short. AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market in Sweden. Learn more at www.acucort.com (http://file:///C:/Users/kund/Desktop/www.acucort.com).